Literature DB >> 23591488

Bone diseases: bisphosphonates in osteoporosis--beyond 5 years.

Socrates E Papapoulos.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23591488     DOI： 10.1038/nrrheum.2013.57

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN： 1759-4790            Impact factor:   20.543


× No keyword cloud information.
  10 in total

1.  Prolonged bisphosphonate release after treatment in children.

Authors:  Socrates E Papapoulos; Serge C L M Cremers
Journal:  N Engl J Med       Date:  2007-03-08       Impact factor: 91.245

2.  Bisphosphonates for osteoporosis--where do we go from here?

Authors:  Marcea Whitaker; Jia Guo; Theresa Kehoe; George Benson
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

3.  Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial.

Authors:  Dennis M Black; Ann V Schwartz; Kristine E Ensrud; Jane A Cauley; Silvina Levis; Sara A Quandt; Suzanne Satterfield; Robert B Wallace; Douglas C Bauer; Lisa Palermo; Lois E Wehren; Antonio Lombardi; Arthur C Santora; Steven R Cummings
Journal:  JAMA       Date:  2006-12-27       Impact factor: 56.272

4.  Effect of stopping risedronate after long-term treatment on bone turnover.

Authors:  Richard Eastell; Rosemary A Hannon; Dietrich Wenderoth; Jesus Rodriguez-Moreno; Andrzej Sawicki
Journal:  J Clin Endocrinol Metab       Date:  2011-08-24       Impact factor: 5.958

5.  Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial.

Authors:  Ann V Schwartz; Douglas C Bauer; Steven R Cummings; Jane A Cauley; Kristine E Ensrud; Lisa Palermo; Robert B Wallace; Marc C Hochberg; Adrianne C Feldstein; Antonio Lombardi; Dennis M Black
Journal:  J Bone Miner Res       Date:  2010-05       Impact factor: 6.741

6.  Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis.

Authors:  S A Khan; J A Kanis; S Vasikaran; W F Kline; B K Matuszewski; E V McCloskey; M N Beneton; B J Gertz; D G Sciberras; S D Holland; J Orgee; G M Coombes; S R Rogers; A G Porras
Journal:  J Bone Miner Res       Date:  1997-10       Impact factor: 6.741

7.  BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate.

Authors:  Brian Louis McNabb; Eric Vittinghoff; Ann V Schwartz; Richard Eastell; Douglas C Bauer; Kristine Ensrud; Elizabeth Rosenberg; Arthur Santora; Elizabeth Barrett-Connor; Dennis M Black
Journal:  J Bone Miner Res       Date:  2013-06       Impact factor: 6.741

8.  Skeletal metabolism in patients with osteoporosis after discontinuation of long-term treatment with oral pamidronate.

Authors:  J O Landman; N A Hamdy; E K Pauwels; S E Papapoulos
Journal:  J Clin Endocrinol Metab       Date:  1995-12       Impact factor: 5.958

9.  Continuing bisphosphonate treatment for osteoporosis--for whom and for how long?

Authors:  Dennis M Black; Douglas C Bauer; Ann V Schwartz; Steven R Cummings; Clifford J Rosen
Journal:  N Engl J Med       Date:  2012-05-09       Impact factor: 91.245

10.  The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT).

Authors:  Dennis M Black; Ian R Reid; Steven Boonen; Christina Bucci-Rechtweg; Jane A Cauley; Felicia Cosman; Steven R Cummings; Trisha F Hue; Kurt Lippuner; Peter Lakatos; Ping Chung Leung; Zulema Man; Ruvie Lou Maria Martinez; Monique Tan; Mary Ellen Ruzycky; Guoqin Su; Richard Eastell
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741
  10 in total
  3 in total

Review 1.  Osteoporosis Treatment: When to Discontinue and When to Re-start.

Authors:  Silvano Adami; Luca Idolazzi; Elena Fracassi; Davide Gatti; Maurizio Rossini
Journal:  Bone Res       Date:  2013-12-31       Impact factor: 13.567

2.  Andrographolide stimulates osteoblastogenesis and bone formation by inhibiting nuclear factor kappa-Β signaling both in vivo and in vitro.

Authors:  Chang Yongyun; Zhang Jingwei; Liu Zhiqing; Chu Wenxiang; Li Huiwu
Journal:  J Orthop Translat       Date:  2019-03-02       Impact factor: 5.191

3.  Low pH constructed Co(ii) and Ni(ii) 1D coordination polymers based on Cα-substituted analogues of zoledronic acid: structural characterization, and spectroscopic and magnetic properties.

Authors:  Tomasz Rojek; Waldemar Goldeman; Katarzyna Ślepokura; Marek Duczmal; Agnieszka Wojciechowska; Ewa Matczak-Jon
Journal:  RSC Adv       Date:  2019-10-07       Impact factor: 4.036
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.